CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of Boceprevir triple therapy in previously treated patients with HCV Genotype 1 (G1) infection in German real-life
DOI 10.1055/s-0035-1567991
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe12/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Since 2011, triple therapy with the HCV protease inhibitor boceprevir (BOC) is widely used as standard of care for patients (pts) with chronic HCV G1 infection. The present interim analysis of the NOVUS observational study investigated the efficacy and safety of BOC triple therapy in pretreated patients in German real-world according to the previous virologic response to dual therapy with pegylated inter…
Zitieren
Zitierempfehlung
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer (2015) Efficacy and safety of Boceprevir triple therapy in previously treated patients with HCV Genotype 1 (G1) infection in German real-life. Zeitschrift für Gastroenterologie (12). https://doi.org/10.1055/s-0035-1567991
Mit CareLit weiterarbeiten